(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Status: Recruiting
Location: See all (25) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Primary localized uveal melanoma requiring either enucleation or plaque brachytherapy
• Able to dose orally
• ECOG Performance status of 0-1
• No other significant underlying ocular disease
• Adequate organ function
• Not pregnant/nursing or planning to become pregnant. Willing to use birth control
Locations
United States
Arizona
HonorHealth Research Institute
RECRUITING
Scottsdale
California
Moores Cancer Center
RECRUITING
La Jolla
UCLA Medical Center
RECRUITING
Los Angeles
Stanford Cancer Institute
RECRUITING
Palo Alto
Colorado
Sarah Cannon Research Institute
RECRUITING
Denver
Florida
University of Miami
RECRUITING
Miami
Michigan
The Cancer and Hematology Centers
RECRUITING
Grand Rapids
Minnesota
Mayo Clinic Rochester
RECRUITING
Rochester
North Carolina
Duke University Health System
WITHDRAWN
Durham
New York
Northwell
RECRUITING
Manhasset
Pennsylvania
Thomas Jefferson University
RECRUITING
Philadelphia
Tennessee
Sarah Cannon Research Institute
RECRUITING
Nashville
Texas
University of Texas Southwestern Medical Center
RECRUITING
Dallas
Other Locations
Australia
Alfred Health
RECRUITING
Melbourne
St. Vincent's Health Sydney
RECRUITING
Sydney
Canada
Princess Margaret Cancer Centre
RECRUITING
Toronto
France
Institute Curie
RECRUITING
Paris
Germany
Charité - Universitätsmedizin Berlin
RECRUITING
Berlin
University Hospital Essen - West German Cancer Center
NOT_YET_RECRUITING
Essen
Italy
Fondazione IRCCS Istituto Nazionale Tumori
RECRUITING
Milan
Instituto Nazionale Tumori IRCCS - Fondazione Pascale
NOT_YET_RECRUITING
Napoli
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RECRUITING
Rome
Netherlands
Leiden University Medical Center
RECRUITING
Leiden
United Kingdom
University College London Hospital - NHS Foundation Trust
RECRUITING
London
The Clatterbridge Cancer Centre NHS Foundation Trust
RECRUITING
Metropolitan Borough Of Wirral
Contact Information
Primary
IDEAYA Clinical Trials
IDEAYAClinicalTrials@ideayabio.com
+1-855-433-2246
Backup
Jasgit Sachdev, MD
jsachdev@ideayabio.com
Time Frame
Start Date: 2023-07-03
Estimated Completion Date: 2029-01-31
Participants
Target number of participants: 82
Treatments
Experimental: darovasertib
IDE196 (darovasertib) oral open label
Related Therapeutic Areas
Sponsors
Leads: IDEAYA Biosciences